Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - OWC Pharmaceutical Research Corp.Financial_Report.xls
EX-32 - EXHIBIT 32.1 - OWC Pharmaceutical Research Corp.exh32_1.htm
EX-32 - EXHIBIT 32.2 - OWC Pharmaceutical Research Corp.exh32_2.htm
EX-31 - EXHIBIT 31.2 - OWC Pharmaceutical Research Corp.exh31_2.htm
EX-31 - EXHIBIT 31.1 - OWC Pharmaceutical Research Corp.exh31_1.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________

FORM 10-Q
___________________

ý                                  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2015

Commission file number 0-54856

OWC PHARMACEUTICAL RESEARCH CORP.
(Exact Name of Registrant in its Charter) 

Delaware 98-0573566
(State or other Jurisdiction of Incorporation) (IRS Employer Identification No.)
 

22 Shaham Steet, P.O. Box 8324, Petach Tikva, 4918103, Israel
(Address of Registrant’s Principal Executive Offices and Principal Place of Business)
 

Registrant's Telephone Number, Including Area Code: Phone: +972 (0) 3-758-2657

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer (as defined in Rule 12b-2 of the Exchange Act) or a smaller reporting company.

Large accelerated filer ¨ Accelerated filer ¨ Non-Accelerated filer ¨ Smaller reporting company x

On April 15, 2015, the Registrant had 79,229,273 shares of common stock outstanding.





 

TABLE OF CONTENTS

Item
Description
Page
 
PART I - FINANCIAL INFORMATION
 
ITEM 1.    FINANCIAL STATEMENTS - UNAUDITED. 3
     Consolidated Balance Sheets 3
     Consolidated Statements of Operations 4
     Consolidated Statements of Comprehensive Loss 5
     Consolidated Statements of Cash Flows 6
     Notes to Unaudited Interim Consolidated Financial Statements 7
ITEM 2.    MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS. 14
ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. 17
ITEM 4.    CONTROLS AND PROCEDURES. 18
   
PART II - OTHER INFORMATION
   
ITEM 1.    LEGAL PROCEEDINGS. 18
ITEM 1A.    RISK FACTORS. 18
ITEM 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. 18
ITEM 3.    DEFAULT UPON SENIOR SECURITIES. 18
ITEM 4.    MINE SAFETY DISCLOSURE. 18
ITEM 5.    OTHER INFORMATION. 18
ITEM 6.    EXHIBITS. 18

 



PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS Back to Table of Contents

 

OWC Pharmaceutical Research Corp.
Consolidated Balance Sheets
At March 31, 2015 and December 31, 2014
Back to Table of Contents
  March 31, 2015
(Unaudited) December 31, 2014
ASSETS
Current assets:
   Cash $ 1,165,638 $ 1,469,267
   Other current assets   -   24,091
      Total current assets 1,165,638 1,493,358
 
   Property and equipment, net 28,903 29,454
   
        Total Assets $ 1,194,541 $ 1,522,812
 
LIABILITIES AND STOCKHOLDERS' EQUITY
 
Current liabilities:
   Accounts payable - trade $ 37,309 $ 16,523
   Accrued expenses   2,949   43,643
   Advances and accounts payable to related parties - 138
   Total current liabilities 40,258 60,304
 
Total liabilities 40,258 60,304
 
Stockholders' equity:
   Preferred stock, $0.00001 par value; 20,000,000 shares authorized; no shares issued and outstanding - -
   Common stock, $0.00001 par value; 500,000,000 shares authorized; and
     79,729,273 and 78,429,241 issued and outstanding at March 31, 2015 and December 31, 2014, respectively 797 784
   Additional paid in capital 8,052,175 8,000,847
   Common stock subscription receivable (651,730) (651,730)
   Subscription payable 50,000 -
   Accumulated deficit (6,298,486) (5,893,878)
   Accumulated other comprehensive income   1,527   6,485
     Total stockholders' equity 1,154,283 1,462,508
       Total liabilities and stockholders' equity $ 1,194,541 $ 1,522,812
 
See notes to unaudited interim consolidated financial statements.

 

Page 3


OWC Pharmaceutical Research Corp.
Consolidated Statements of Operations
For the Three Months Ended March 31, 2015 and 2014
(Unaudited)
Back to Table of Contents
For the three months For the three months
ended March 31, 2015 ended March 31, 2014
  

Revenues

$

-

$

-

 
Expenses
   General and administrative

305,479

472,142

   Research and development

99,124

-

 
Loss from operations (404,603) (472,142)
 
Other income (expense):
   Amortization of debt discount

-

(36,871)

Total other expense - (36,871)
   Total costs and expenses (404,603) (509,013)
 
Net loss before income taxes (404,603) (509,013)
Income tax

-

-

 
Net loss

$

(404,603)

$

(509,013)

 
Basic and diluted per share amounts:
Basic and diluted net loss

$

(0.01)

$

(0.02)

 
Weighted average shares outstanding (basic and diluted)

79,729,241

29,358,306

 
See notes to unaudited interim consolidated financial statements.

Page 4


 

OWC Pharmaceutical Research Corp.
Consolidated Statements Comprehensive Loss
For the Three Months Ended March 31, 2015 and 2014
(Unaudited)
Back to Table of Contents
For the three months For the three months
ended March 31, 2015 ended March 31, 2014
  
Net loss $ (404,603) $ (509,013)
 
Other comprehensive income, net of tax:
   Foreign currency translation adjustments (4,958) -
Total other comprehensive income, net of tax (4,958) -
 
Comprehensive loss $ (409,561) $ (509,013)
See notes to unaudited interim consolidated financial statements.

Page 5


OWC Pharmaceutical Research Corp.
Consolidated Statements of Cash Flows
For the Three Months Ended March 31, 2015 and 2014
(Unaudited)
Back to Table of Contents
For the three months For the three months
ended March 31, 2015 ended March 31, 2014
 

Cash flows from operating activities:

Net loss

$

(404,603)

$

(509,013)

Adjustments to reconcile net loss to net cash used in operating activities:
   Amortization of debt discount - 34,034
   Depreciation 2,181 -
   Common stock issued for services 500 455,430
   Fair value of warrants issued for services 10,839 -
Changes in net assets and liabilities:
   (Increase) decrease in other current assets 24,090 -
   Accounts payable - related party (138) -
   Increase (decrease) in accounts payable 20,788 -
   Increase (decrease) in accrued expenses

(40,697)

2,837

Cash used in operating activities

(387,040)

(16,712)

  
Cash flow from investing activities:
   Purchase of equipment (1,630) -
Cash used in investing activities

(1,630)

-

         
         
Cash flow from financing activities:
   Proceeds from issuance of common stock 90,000 8,750
   Proceeds of debt borrowings - 14,500
Cash provided by financing activities

90,000

23,250

  
Foreign currency translation

(4,958)

-

         
Change in cash

(303,628)

6,538

Cash - beginning of period

1,469,267

2,469

Cash - end of period

$

1,165,638

$

9,007

 
Supplement cash flow information:
Non-cash transactions:
   Debt and accrued interest converted to equity $ - $ 130,849
 
See notes to unaudited interim consolidated financial statements.

Page 6


OWC Pharmaceutical Research Corp.
Notes to Unaudited Interim Consolidated Financial Statements
Back to Table of Contents

1. The Company and Significant Accounting Policies

Organizational Background:   OWC Pharmaceutical Research Corp. ("OWCP" or the "Company") is a Delaware corporation and was incorporated under the laws of the State of Delaware on March 7, 2008.

The Company is engaged in two distinct business activites: (i) work with GUMI to commercialize and market the Company's Electromagnetic Percussion Device (the "Device"); and (ii) research and development of Cannabis-based medical products for the treatment of a variety of medical conditions and/or diseases such as multiple myeloma, psoriasis, PTSD, migraines and a unique delivery system.

The accompanying financial statements of OWCP were prepared from the accounts of the Company under the accrual basis of accounting.

Basis of Presentation:   The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has not established any source of revenue to cover its operating costs, and as such, has incurred an operating loss since inception. These and other factors raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

Principles of Consolidation:   The financial statements include the accounts of OWC Pharmaceutical Research Corp. and its wholly owned subsidiary One World Cannabis, Inc. (OWC). All significant inter-company balances and transactions have been eliminated.

Significant Accounting Policies

Use of Estimates:   The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.

Cash and Cash Equivalents:   For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. There were no cash equivalents at March 31, 2015 and December 31, 2014.

Property and Equipment:   New property and equipment are recorded at cost. Property and equipment included in the bankruptcy proceedings and transferred to the Trustee had been valued at liquidation value. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally 5 years. Expenditures for renewals and betterments are capitalized. Expenditures for minor items, repairs and maintenance are charged to operations as incurred. Gain or loss upon sale or retirement due to obsolescence is reflected in the operating results in the period the event takes place.

Valuation of Long-Lived Assets:   We review the recoverability of our long-lived assets including equipment, goodwill and other intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on our ability to recover the carrying value of the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value. Our primary measure of fair value is based on discounted cash flows. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations.

Foreign Currency:   Non-U.S. entity operations are recorded in the functional currency of each entity. Results of operations for non-U.S. dollar functional currency entities are translated into U.S. dollars using average currency rates. Assets and liabilities are translated using currency rates at period end. Foreign currency translation adjustments are recorded as a component of other comprehensive income (loss) within stockholders' equity.

Stock Based Compensation:   Stock-based awards are accounted for using the fair value method in accordance with ASC 718, Share-Based Payments. Our primary type of share-based compensation consists of stock options. We use the Black-Scholes option pricing model in valuing options. The inputs for the valuation analysis of the options include the market value of the Company's common stock, the estimated volatility of the Company's common stock, the exercise price of the warrants and the risk free interest rate.

Accounting For Obligations And Instruments Potentially To Be Settled In The Company's Own Stock:   We account for obligations and instruments potentially to be settled in the Company's stock in accordance with FASB ASC 815, Accounting for Derivative Financial Instruments. This issue addresses the initial balance sheet classification and measurement of contracts that are indexed to, and potentially settled in, the Company's own stock.

Fair Value of Financial Instruments:   FASB ASC 825, "Financial Instruments," requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value. FASB ASC 825 defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. At March 31, 2015 and December 31, 2014, the carrying value of certain financial instruments (cash and cash equivalents, accounts payable and accrued expenses.) approximates fair value due to the short-term nature of the instruments or interest rates, which are comparable with current rates.

Fair Value Measurements:   The Company measures fair value under a framework that utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of inputs which prioritize the inputs used in measuring fair value are:

Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.

Level 2: Inputs to the valuation methodology include:

- Quoted prices for similar assets or liabilities in active markets;
- Quoted prices for identical or similar assets or liabilities in inactive markets;
- Inputs other than quoted prices that are observable for the asset or liability;
- Inputs that are derived principally from or corroborated by observable market data by correlation or other means.

If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The assets or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. The following table presents assets that were measured and recognize at fair value on March 31, 2015 and December 31, 2014 and the year then ended on a recurring basis:

Fair Value Measurements at March 31, 2015
Quoted Prices in Active Significant Other Significant
Markets for Identical Assets Observable Inputs Unobservable Inputs

Total

(Level 1)

(Level 2)

(Level 3)

None

$

-

$

-

$

-

$

-
Total assets at fair value

$

-

$

-

$

-

$

-

 

Fair Value Measurements at December 31, 2014
Quoted Prices in Active Significant Other Significant
Markets for Identical Assets Observable Inputs Unobservable Inputs

Total

(Level 1)

(Level 2)

(Level 3)

None

$

-

$

-

$

-

$

-
Total assets at fair value

$

-

$

-

$

-

$

-

When the Company changes its valuation inputs for measuring financial assets and liabilities at fair value, either due to changes in current market conditions or other factors, it may need to transfer those assets or liabilities to another level in the hierarchy based on the new inputs used. The Company recognizes these transfers at the end of the reporting period that the transfers occur. For the fiscal periods ended March 31, 2015 and December 31, 2014, there were no significant transfers of financial assets or financial liabilities between the hierarchy levels.

Earnings per Common Share:   We compute net income (loss) per share in accordance with ASC 260, Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. All per share disclosures retroactively reflect shares outstanding or issuable as though the reverse split had occurred January 1, 2010.

Income Taxes:   We have adopted ASC 740, Accounting for Income Taxes. Pursuant to ASC 740, we are required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.

We must make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes.

Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities using the tax rates and laws in effect when the differences are expected to reverse. ASC 740 provides for the recognition of deferred tax assets if realization of such assets is more likely than not to occur. Realization of our net deferred tax assets is dependent upon our generating sufficient taxable income in future years in appropriate tax jurisdictions to realize benefit from the reversal of temporary differences and from net operating loss, or NOL, carryforwards. We have determined it more likely than not that these timing differences will not materialize and have provided a valuation allowance against substantially all of our net deferred tax asset.

Management will continue to evaluate the realizability of the deferred tax asset and its related valuation allowance. If our assessment of the deferred tax assets or the corresponding valuation allowance were to change, we would record the related adjustment to income during the period in which we make the determination. Our tax rate may also vary based on our results and the mix of income or loss in domestic and foreign tax jurisdictions in which we operate.

In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for anticipated tax audit issues in the U.S. and other tax jurisdictions based on our estimate of whether, and to the extent to which, additional taxes will be due. If we ultimately determine that payment of these amounts is unnecessary, we will reverse the liability and recognize a tax benefit during the period in which we determine that the liability is no longer necessary. We will record an additional charge in our provision for taxes in the period in which we determine that the recorded tax liability is less than we expect the ultimate assessment to be.

ASC 740 which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.

Uncertain Tax Positions:   When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of FASB ASC 740-10, Accounting for Uncertain Income Tax Positions, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

Our federal and state income tax returns are open for fiscal years ending on or after December 31, 2010. We are not under examination by any jurisdiction for any tax year. At March 31, 2015 we had no material unrecognized tax benefits and no adjustments to liabilities or operations were required under FASB ASC 740-10.

Recent Accounting Pronouncements

On June 10, 2014, the FASB issued Accounting Standards Update ("ASU") No. 2014-10 , which eliminates development stage reporting requirements under FASB ASC 915, as well as amends provisions of existing variable interest entity guidance under ASC 810. Additionally, the ASU indicates that the lack of commencement of principal operations represents a risk and uncertainty and, accordingly, is subject to the disclosure requirements of FASB ASC 275. As a result of the changes, existing development stage entity presentation and disclosure requirements are eliminated. The presentation and disclosure changes to FASB ASC 915 are effective for public entities for annual periods beginning after December 15, 2014, and the revisions to the consolidation standards are effective for annual periods beginning after December 15, 2015. The Company has adopted these provisions and enhanced disclosure of risks and uncertainties as required.

In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern . The new standard requires management of public and private companies to evaluate whether there is substantial doubt about the entity's ability to continue as a going concern and, if so, disclose that fact. Management will also be required to evaluate and disclose whether its plans alleviate that doubt. The standard requires management to evaluate, for each reporting period, whether there are conditions or events that raise substantial doubt about a company's ability to continue as a going concern within one year from the date the financial statements are issued. The new standard is effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted. We do not expect the adoption of the ASU to have a significant impact on our consolidated financial statements.

On November 2014, The Financial Accounting Standards Board (FASB) issued Accounting Standard Update No. 2014-16 - Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity (a consensus of the FASB Emerging Issues Task Force). The amendments in this Update do not change the current criteria in GAAP for determining when separation of certain embedded derivative features in a hybrid financial instrument is required. That is, an entity will continue to evaluate whether the economic characteristics and risks of the embedded derivative feature are clearly and closely related to those of the host contract, among other relevant criteria. The amendments clarify how current GAAP should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. The effects of initially adopting the amendments in this Update should be applied on a modified retrospective basis to existing hybrid financial instruments issued in the form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods.

On November 2014, The Financial Accounting Standards Board (FASB) issued Accounting Standard Update No. 2014-17 - Business Combinations (Topic 805): Pushdown Accounting (a consensus of the FASB Emerging Issues Task Force). The amendments in this Update provide an acquired entity with an option to apply pushdown accounting in its separate financial statements upon occurrence of an event in which an acquirer obtains control of the acquired entity. The amendments in this Update are effective on November 18, 2014. After the effective date, an acquired entity can make an election to apply the guidance to future change-in-control events or to its most recent change-in-control event. However, if the financial statements for the period in which the most recent change-in-control event occurred already have been issued or made available to be issued, the application of this guidance would be a change in accounting principle.

Management does not anticipate that the adoption of these standards will have a material impact on the financial statements.

The Financial Statements presented herein have been prepared by us in accordance with the accounting policies described in our December 31, 2014 Annual Report and should be read in conjunction with the Notes to Financial Statements which appear in that report.

The preparation of these financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related intangible assets, income taxes, insurance obligations and contingencies and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other resources. Actual results may differ from these estimates under different assumptions or conditions.

In the opinion of management, the information furnished in these interim financial statements reflects all adjustments necessary for a fair statement of the financial position and results of operations and cash flows as of and for the three-month periods ended March 31, 2015 and 2014. All such adjustments are of a normal recurring nature. The Financial Statements do not include some information and notes necessary to conform to annual reporting requirements.

2. Stockholders' Equity

Common Stock

Recent Issuances of Common Stock - for the Period Ended March 31, 2015:

Stock Issued for cash: In February of 2015, we sold 800,000 shares to one investor for the offering price of $0.05 per share that resulted in total proceeds of $40,000. During 2015 the first quarter of 2015, we also received $50,000 through a placement of common stock units. Those units were sold at $0.15 per unit. Each unit consisted of one share of common stock and one warrant to purchase common stock. On February 16, 2015, we issued 500,000 shares for consulting services valued at $500 based on the fair market value of the stock on the date of issuance. These shares were subsequently cancelled in April 2015.

Historical Activity in 2014:

Stock Issued upon conversion of debt: On July 1, 2014 we issued 179,300 shares of our common stock in settlement of $1,500 in convertible note payable plus associated accrued interest of $293. The conversion occurred within the terms of the promissory note and no gain or loss resulted. On February 28, 2014 we issued 13,084,000 shares of our common stock in settlement of $114,414 in convertible note payable plus associated accrued interest of $16,435. The conversion occurred within the terms of the promissory note and no gain or loss resulted.

Stock Issued for Services: During the interim period ended September 30, 2014 we issued 300,000 shares of our common stock to an unrelated party as payment for services. We also issued 400,000 shares to two former officers and directors of the company as part of a severance agreement. The shares were valued at the closing price as of the date of the agreements ($0.25 and $0.28, respectively) and resulted in full recognition of $187,000 in consulting services expense. During the interim periods ended on or before June 30, 2014 we issued 9,208,600 shares of our common stock to seven unrelated parties as payment for services. The shares were valued at the closing price as of the date of the agreement ($0.05) and resulted in full recognition of $481,430 in consulting services expense. In June we cancelled 3,108,600 of these shares valued at $155,430 resulting in $305,000 in consulting expense through September 30, 2014.

Options Issued for Services: During the interim period ended September 30, 2014 we issued 14,350,000 common stock options. 350,000 of those options valued at $82,640 were granted to former related parties while 14,000,000 options valued at $3,774,496 were granted for services provided by unrelated parties.

The fair value of the options was estimated at the date of grant using the Black-Sholes-Merton pricing model. The Black-Sholes-Merton pricing model assumptions used are as follows: expected dividend yield of 0%; risk-free interest rate of 0.47% to 0.49%; expected volatility of 241%, and warrant term of two years.

Stock Issued for cash: In connection with a private placement of 10,000,000 shares of common stock in March and April of 2014 we sold 4,700,000 shares to six investors for the offering price of $0.005 per share that resulted in total proceeds of $23,500. During 2014 we received $1,164,300 through a placement of common stock units. Those units were sold at $0.09 per unit. Each unit consisted of one share of common stock and one warrant to purchase common stock. We issued 12,936,662 shares through September 30th to 22 investors of this offering. The warrants are exercisable at $0.16 and expire in June, 2015. During 2014 we received $554,200 through a placement of common stock units. Those units were sold at $0.15 per unit. Each unit consisted of one share of common stock and one warrant to purchase common stock. We issued 3,694,666 shares through September 30th to 4 investors of this offering. The warrants are exercisable at $0.16 and expire in June, 2015.

Warrants

In February, 2015 we issued 64,935 warrants for services. The warrants are exercisable at $0.25 and expire February 23, 2016. We used the Black-Scholes-Merton pricing model and inputs described below to estimate the fair value of $10,839. The Black-Sholes-Merton pricing model assumptions used are as follows: expected dividend yield of 0%; risk-free interest rate of 0.10% - 0.11%; expected volatility of 242%, and warrant exercise periods based upon the stated terms.

3. Related Party Transactions Not Disclosed Elsewhere

Due Related Parties: We had no related party transactions during the first quarter of 2015. Amounts due related parties totaled $0 at March 31, 2015 and $138 at December 31, 2014, respectively.

4. Notes Payable

Unsecured Notes Payable With No Conversion Rights

During 2014 the Company signed a series of three new unsecured promissory notes with unrelated parties for an aggregate of $14,500. The notes bear interest at 1% per annum and are due one year from the date of issuance. The notes were paid in full in 2014.

Unsecured Notes Payable With Conversion Rights

In February 28, 2014 eleven holders of convertible notes with an aggregate principal balance of $114,414 and accrued interest of $16,435 converted their notes and accrued interest into 13,084,000 shares of common stock. Upon conversion, $34,034 of unamortized discount arising from the previously recorded beneficial conversion feature was recognized as additional interest expense. The conversion occurred within the terms of the promissory note and no gain or loss resulted.

5. Future Commitment and Issuance of Warrants

On March 5, 2013, the Company and GUMI Tel Aviv Ltd, a major, privately-held Israeli technology company ("GUMI"), entered into development/manufacturing/marketing agreement ("GUMI Agreement"). GUMI is engaged in the manufacture, import/export, marketing and install industrial equipment and designing technical solutions.

Pursuant to the GUMI Agreement, GUMI agreed to: (i) complete the development of the Prototype of the Patented Device; (ii) manufacture the commercial model(s) of the Patented device; and (iii) market the commercial model(s) of the Patented Device.

In consideration for developing the Prototype and manufacturing and marketing/distributing commercial models of the Patented Device as well as incurring all related costs and expenses in connection therewith, the Company shall compensate GUMI as follows: (i) upon the execution of the GUMI Agreement, the Company granted GUMI warrants (the "Warrants") exercisable to purchase 200,000 shares of the Company's common stock ("Warrant Shares") at an exercise price of USD$0.05 per share (the "Exercise Price"); (ii) upon completion of the Prototype, granting GUMI additional Warrants to purchase 200,000 additional Warrant Shares at the Exercise Price; and (iii) upon completion of a Commercial Device ready for manufacture and sale, granting GUMI additional Warrants to purchase 200,000 additional Warrant Shares at the Exercise Price. The Warrants shall expire 3 years from the date of each grant and shall be subject to adjustment in the event of any recapitalization of the Company's capital stock.

In addition to the consideration represented by the grant of Warrants, the Agreement further provides that following commencement of sale of the Commercial Device and until such time that GUMI has recouped all costs and expenses that it has incurred and paid in connection with the completion of development of the Prototype and the manufacture of the Commercial Device ("Date of Recoupment"), one hundred (100%) percent of the net sales revenues shall be paid and distributed to GUMI. On and after the Date of Recoupment, net sales revenues shall be paid sixty-five (65%) percent to GUMI and thirty-five (35%) percent to the Company.

The Company recorded $107,074 in fiscal year 2013 in expenses related to 600,000 vested warrants previously granted to GUMI Tel Aviv Ltd. The warrants were valued using the Black-Scholes option pricing model. The inputs for the valuation analysis of the warrants include the market value of the Company's common stock were as follows: the estimated volatility of the Company's common stock used in the Black-Scholes option pricing model was 318%, the exercise price and the risk free interest rate used were $0.05 and 0.36%, respectively. All warrants are fully vested.

6. Going Concern

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has not established any source of revenue to cover its operating costs, and as such, has incurred an operating loss since inception. Further, as of March 31, 2015, the cash resources of the Company were insufficient to meet its current business plan. These and other factors raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of asset or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

7. Subsequent Events

On April 21, 2015, we cancelled 500,000 shares previously issued for consulting services.

There were no additional subsequent events following the period ended March 31, 2015 and throughout the date of the filing of Form 10-Q.

Page 13


ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATION Back to Table of Contents

The following discussion contains forward-looking statements. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use of words such as "anticipate", "estimate", "expect", "project", "intend", "plan", "believe", and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. From time to time, we also may provide forward-looking statements in other materials we release to the public.

Plan of Operations

We are engaged in two distinct business sectors and we may require additional capital to implement our business plan and fund our operations.

Our two distinct business operations are:

(i) continuing to work with GUMI to commercialize and market the Company's Electromagnetic Percussion Device (the "Device"); and
(ii) research and development of Cannabis-based medical products for the treatment of a variety of medical conditions and/or diseases such as multiple myeloma, psoriasis, PTSD, migraines and a unique delivery system.

In 2008, we acquired the patent for our Device and from 2008 until 2011, we devoted our limited resources and efforts to the development of our Device. During late 2011 and into 2012, we renewed our interest in pursuing development of our Device and, subsequent to our year ended December 31, 2012, we entered into an agreement with GUMI to develop a Device prototype, which was successfully completed. GUMI has completed the manufacture of several commercial models of the Device that GUMI is presently devoting resources to market under the terms of our agreement. We continue to be dependent upon the ability of GUMI to successfully market our Device, which process has started. However, we have not yet derived any revenues from GUMI's on-going marketing efforts, which commenced in late 2013 and are continuing in 2015.

We will utilize the capital it recently raised to fund OWC's business including the assembly of a professional team of highly-qualified medical/scientific experts together with experienced management and marketing executives to develop and grow OWC's business.

Our goal is to become an industry leader in the research and development of cannabidiol-based medical drugs and treatments. To achieve our goal, we plan to focus our activities on the following areas:

Research and Development

Our focus is to actively participate with leading Israeli hospitals and institutions in studies and clinical trials designed to develop cannabis-based products, sometimes referred to as "Prospect Products" for the treatment of various diseases and medical conditions. These efforts will include the cultivation of new Cannabis strains aimed at specific medical conditions in patients such as stage of disease and patient characteristics.

In April 2015, we received preliminary results on the effect of several combinations of cannabinoil (CBD) and tetrahydrocannabidoil (THC) on multiple myeloma cells. Multiple Myeloma, a cancer of plasma cells, accounts for 10% of all hematologic malignancies. It is the second most common hematologic cancer and represents 1% of all cancer diagnoses and 2% of all cancer deaths.

The basic science phase of the study began during the first quarter of 2015 at Sheba Academic Medical Center Multiple Myeloma Research Lab. Dr. Merav Leiba, Head of Sheba's Multiple Myeloma Outpatient Clinic and Multiple Myeloma Research Lab is leading the study. The company conducts the study in accordance with Sheba's Internal Review Board (IRB) approval. This study is conducted based on a collaboration agreement with the Sheba Academic Medical Center.

On April 22, 2015, we entered into agreement with G.C. Group to develop new formulations and delivery methods targeting several medical indications. Under the terms of the agreement, G.C. Group Ltd., an Israeli pharmaceutical R&D company, engaged in development of a variety of innovative and generic drug products of different types. G.C. Group Ltd. will develop cannabinoid-based oil formulations that will be tested with unique delivery methods.

We will continue to center our research and development on Cannabis-based Prospect Products, in order to distinguish our Prospect Products from unrefined herbal cannabis products and their derivatives that are now being used by other medical practitioners and companies in our industry.

Unlike other companies, we will not engage in the preparation, production and distribution of unrefined and non-standardized forms of herbal cannabis-related products for clinical testing or medical use. Most herbal cannabis products are inexact in dosing and administration and are not consistent in effect.

Our Prospect Products will be tested in controlled, pre-clinical and clinical studies conducted at leading Israeli hospitals and scientific institutions, adhering to strict protocols so as to comply will all applicable of regulatory authorities.

In order to obtain the requisite regulatory approvals for our Prospect Products, all human clinical testing will be conducted in collaboration with our university and hospital partners.

Our research and development efforts will also focus on creating new Prospect Products in custom combinations from extracted cannabinoids, for initial testing at the pre-clinical level. Our research and development plan is for the initial, custom-made strains of our Prospect Products to be scientifically analyzed through our relationships with our respected research organization partners. The most promising Cannabis-based Prospect Products in each disease category will be used in human clinical trial phase I (safety), phase II (efficacy over time-limited), and phase III (efficacy over time with full subject enrollment).

We will be working closely with local, national and international regulatory agencies in Israel, the U.S., Europe and in South America and Asia for the purpose of providing access to our Cannabis-based Prospect Products and therapies to patients in need of new treatments for life threatening and debilitating conditions as well as improving quality of life for those with long-term illnesses.

There can be no assurance of our ability to generate revenues or profits. Extensive clinical trials establishing the safety and efficacy of our Cannabis-based Prospect Products treating our targeted medical conditions and/or diseases is necessary and the length of time needed to establish the safety and efficacy as well as the competitive, cost-effective benefits, if any, of our Prospect Products cannot be assured.

Regional and International Promotion of Cannabis Research

OWC's facilities in Petach Tikva Israel serve as the center for our research and development activity in coordination with the studies and trials being conducted with several Israeli hospitals and universities. We also intend to establish additional research centers outside of Israel for the purpose of collaborating in Cannabis-based medical research with other hospital and research institutes.

Under the direction of Drs. Yehuda Baruch and Alan Shackelford, OWC's management team is working with its research partners to identify and prioritize investigations into several health-related medical conditions they believe will respond positively to our Cannabis-based Prospect Products. As in Israel, we will select those of our Prospect Products that we deem most effective after initial testing for further clinical studies to verify the results and to determine specific quantitative parameters for the commercialization of our Cannabis-based Prospect Products.

Government and Public Agency Consulting

Our initial activities will be focused on the United States and on the European Community countries that have not yet passed legislation to fully legalize medical Cannabis. By working with governments and public agencies to establish the infrastructure necessary for the safe care and management of patients using our Cannabis-based medical products generally and our Prospect Products specifically, we believe that we will be able to raise awareness in the medical community and the public at large of the efficacy of cannabis-based treatments. We believe that these efforts will assist in promoting the establishment of national, regional and local programs beyond Israel to encourage the legalization of cannabis for medical purposes and the use of our Cannabis-based Prospect Products.

OWC will assist in the creation of programs tailored to meet the specific medical needs of a given market. This includes the development of a regulatory framework and operating infrastructure. OWC's team of experts also have vast experience in developing the training programs for physicians, caregivers, and researchers that are essential to the establishment of a successful, patient-focused medical cannabis program.

In furtherance of our plans, we may, in the future, consider strategic acquisitions and joint ventures as well as other projects to grow our business activities including but not limited to: product licensing and royalty agreements, consulting, and strategic alliances to support our Cannabis-based Prospect Product development. However, there can be no assurance that this strategy will be successful in generating any revenues or growing out business.

Based upon our cash position of $1,165,638 at March 31, 2015, we believe that we may need to raise additional capital, either equity or debt prior to the end of fiscal 2015 in order to fund our plan of operations including our research and development initiatives for the next twelve months. There can be no assurance, however, that additional capital will be sufficient to fund our currently anticipated expenditure requirements for the next twelve-month period nor can there be any assurance that financing will be available at satisfactory terms and conditions or at all, for that matter.

Our Strengths

We commenced our business to develop Cannabis-based Products since mid 2014 and have not yet generated any revenues from this endeavor. We believe that we offer the following key distinguishing characteristics in our approach to develop and commercialize our Cannabis-based Prospect Products:

Ÿ Our two leading medical professionals are recognized world-leaders in medical cannabis treatments;
Ÿ Our ability to obtain very quickly an approved Helsinki protocol (IRB) between 3-9 months each;
Ÿ We applied for internal review board (IRB) approval to the multiple myeloma study and to the PTSD study. We have received Sheba Academic Medical Center internal review board (IRB) approval to the multiple myeloma study, and expect to obtain IRB approval to the PTSD study during the second quarter of 2015. We plan to apply for IRB approval of five other studies in 2015;
Ÿ We have filed six provisional patent applications with the USPTO;
Ÿ Collaborations with major Israeli Hospital and research institutes. We have entered into a collaboration agreement with Sheba Medical Center in Israel to research a treatment for multiple myeloma, a highly treatment-resistant form of bone marrow cancer. We expect to enter into additional collaboration agreements by the end of fiscal 2015;
Ÿ Strong competitive position in a highly specialized and regulated field. Several members of our leadership team have been in involved in similar business ventures for over ten years. We have a fully integrated in-house research and development organization, regulatory capabilities and commercial and marketing expertise; and
Ÿ Highly experienced management team and network of leading scientists. We believe that our business development and science team is uniquely positioned to benefit from the significant potential within the field of cannabidiol-based research in which we have developed expertise during over 15 years of research and business development conducted by Drs. Yehuda Baruch and Alan Shackelford. Our science team collaborates with a broad network of other leading scientists in the Cannabis research field.

Our Strategic Alliances and Collaborations

To date, we have entered into a collaboration agreement with Sheba Academic Medical Center, the largest hospital in Israel and in the Middle East. Within the framework of a new collaboration agreement, the Company has initiate one study on multiple myeloma and will initiate one on psoriasis.

We are in the process of finalizing additional collaboration agreements with other research institutes for several additional studies and clinical trials.

Results of Operations during the three months ended March 31, 2015 as compared to the three months ended March 31, 2014

We have not generated any revenue during the three months ended March 31, 2015 and 2014. We have operating expenses related to general and administrative expenses and research and development expenses. During the three months ended March 31, 2015, we incurred a net loss of $404,603 due to general and administrative expenses of $305,479 and research and development expenses of $99,124 compared to a net loss of $509,013 due to general and administrative expenses of $472,142 and amortization of debt discount of 36,871 during the same period in the prior year.

Our general and administrative expenses decreased by $166,663 or 35% during the three month-period ended March 31, 2015 as compared to the same period in the prior year. During the three month-period ended March 31, 2015, we incurred $99,124 in research and development expenses as compared to no such expenses in the same period in the prior year. During the three month-period ended March 31, 2015, we had no amortization of debt discount expenses as compared to $36,871 during the three months ended March 31, 2014.

Our comprehensive net loss during the three months ended March 31, 2015 was $409,561, adjusted by $4,958 due to foreign currency translation adjustments as compared to $509,013 in the same period in the prior year with no adjustments.

Liquidity and Capital Resources

On March 31, 2015, we had total assets of $1,194,541 consisting of $1,165,638 in cash and equipment valued at $28,903. We had total assets of $1,522,812 as of December 31, 2014, consisting of $1,469,267 in cash, $24,091 in other assets and equipment valued at $29,454.

On March 31, 2015, we had $40,258 in liabilities consisting of $37,309 in accounts payable and $2,949 in accrued expenses. On December 31, 2014, we had total liabilities of $60,304 consisting of $16,523 in accounts payable, $43,643 in accrued expenses and $138 in advances and accounts payable to related parties.

We had positive working capital of $1,125,380 at March 31, 2015 and $1,433,054 at December 31, 2014. Our accumulated deficits as of March 31, 2015 and December 31, 2014 were $6,298,486 and $5,893,878, respectively.

We used $387,040 in our operating activities during the three months ended March 31, 2015, which was due to a net loss of $404,603 offset by depreciation expenses of $2,181, shares issued for services valued at $500, warrants issued for services valued at $10,839, decrease in current assets of $24,090, increase in accounts payable of $20,788, an increase of accrued expenses of $40,697 and a decrease in accounts payable to related party of $138.

We used $16,712 in our operating activities during the three month ended March 31, 2014, which was due to a net loss of $509,013 offset by increases in amortization of debt discount of $34,034, non-cash compensation expenses valued at $455,430 and an increase in accrued expenses of $2,837.

We used $1,630 during the three months ended March 31, 2015 to purchase property and equipment. We had no investing activities in the same period in the prior year.

Our financing activities during the three months ended March 31, 2015 provided us with $90,000 related to proceeds from the issuance of 800,000 shares of common stock and 333,333 warrants.

We financed our negative cash flow from operations during the three months ended March 31, 2014 through proceeds from issuance of common stock in the amount of $8,750 and proceeds from the issuance of convertible notes of $14,500, representing total cash generated by financing activities of $23,250.

Based upon our cash position of $1,165,638 at March 31, 2015, we believe that we may need to raise additional capital, either equity or debt prior to the end of fiscal 2015 in order to fund our plan of operations including our research and development initiatives for the next twelve months. There can be no assurance, however, that additional capital will be sufficient to fund our currently anticipated expenditure requirements for the next twelve-month period nor can there be any assurance that financing will be available at satisfactory terms and conditions or at all, for that matter.

Our auditors have issued an opinion on our financial statements for the year 2014, which includes a statement describing our going concern status. This means that there is substantial doubt that we can continue as an on-going business for the next twelve months unless we obtain additional capital to pay our bills and meet our other financial obligations. This is because we have not generated any revenues and no revenues are anticipated until we begin marketing the product. Accordingly, we must raise capital from sources other than the actual sale of the product. We must raise capital to implement our project and stay in business. Even if we raise the maximum amount of money in this offering, we do not know how long the money will last, however, we do believe it will last at least twelve months.

There are no limitations in our articles of incorporation on our ability to borrow funds or raise funds through the issuance of restricted common stock. Our limited resources and lack of operating history may make it difficult to do borrow funds or raise capital. Our inability to borrow funds or raise funds through the issuance of restricted common stock required to facilitate our business plan may have a material adverse effect on our financial condition and future prospects. To the extent that debt financing ultimately proves to be available, any borrowing will subject us to various risks traditionally associated with indebtedness, including the risks of interest rate fluctuations and insufficiency of cash flow to pay principal and interest.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Back to Table of Contents

None.

ITEM 4. CONTROLS AND PROCEDURES Back to Table of Contents

Evaluation of disclosure controls and procedures. As of March 31, 2015, the Company's chief executive officer and chief financial officer conducted an evaluation regarding the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the  Exchange Act. Based upon the evaluation of these controls and procedures, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this report.

Changes in internal controls. During the quarterly period covered by this report, no changes occurred in our internal control over financial reporting that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS Back to Table of Contents

We are not currently subject to any material legal proceedings, nor, to our knowledge, is any material legal proceeding threatened against us. However, from time to time, we may become a party to certain legal proceedings in the ordinary course of business.

ITEM 1A. RISK FACTORS Back to Table of Contents

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1. Description of Business, subheading "Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2014, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Back to Table of Contents

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES Back to Table of Contents

None.

ITEM 4. MINE SAFETY DISCLOSURE. Back to Table of Contents

Not applicable.

ITEM 5. OTHER INFORMATION Back to Table of Contents

Not applicable.

ITEM 6. EXHIBITS Back to Table of Contents

(a) The following documents are filed as exhibits to this report on Form 10-Q or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.

Exhibit No.

Description
31.1 Section 302 Certification of the Sarbanes-Oxley Act of 2002 of the Company's CEO, Mordechai Bignitz, filed herewith.
31.2 Section 302 Certification of the Sarbanes-Oxley Act of 2002 of the Company's CFO, Shmuel De-Saban, filed herewith.
32.1

Section 906 of the Sarbanes-Oxley Act of 2002 of Mordechai Bignitz as CEO, filed herewith

32.2

Section 906 of the Sarbanes-Oxley Act of 2002 of Shmuel De-Saban as CFO, filed herewith

Page 17


SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned.

Signature Title Date
      
/s/ Mordechai Bignitz Chief Executive Officer (Principal Executive Officer) May 15, 2015
Mordechai Bignitz    
       
/s/ Shmuel De-Saban Chief Financial Officer (Principal Financial and Principal Accounting Officer) May 15, 2015
Shmuel De-Saban    
       

Pursuant to the requirements of the Securities Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature Title Date
      
/s/ Mordechai Bignitz Chief Executive Officer May 15, 2015
Mordechai Bignitz    
       
/s/ Mordechai Bignitz Chairman May 15, 2015
Mordechai Bignitz